Founded by pioneers in biopharmaceuticals, Renova Therapeutics is developing a portfolio of definitive gene and peptide therapies to restore health to people suffering from cardiovascular and metabolic diseases. Our investigational therapies are based on carefully validated and proprietary research into disease mechanisms and the founders’ nearly 50 combined years of work in the gene therapy field. This experience enables us to generate an entirely original platform of therapeutics and delivery systems that in a single dose are designed to provide durable, life-long treatments for chronic diseases. Our scientific research, led by Dr. H. Kirk Hammond, appears in numerous peer-reviewed articles that establish the scientific rationale and evidence supporting the development of our pipeline and our novel approach to delivering gene therapies. The first indications the company is pursuing are gene therapy treatments for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company’s lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The Renova Therapeutics pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. OUR MISSION: Creating transformational gene and peptide therapies that treat the most prevalent diseases to restore health and renew life OUR VISION: A future in which we are able to permanently treat chronic diseases with gene and peptide therapies
View Top Employees from Renova TherapeuticsWebsite | http://www.renovatherapeutics.com |
Revenue | $9 million |
Funding | $7.5 million |
Employees | 6 (6 on RocketReach) |
Founded | 2009 |
Address | 11455 El Camino Real Suite 350, San Diego, California 92130, US |
Phone | (858) 461-1837 |
Industry | Biotechnology Research, Manufacturing General, Manufacturing |
Competitors | Ember Therapeutics, LYSOGENE, Sangamo Therapeutics, Inc., Spark Therapeutics, Inc., bluebird bio |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies |
Looking for a particular Renova Therapeutics employee's phone or email?
The Renova Therapeutics annual revenue was $9 million in 2024.
Roy Cosan is the President of Renova Therapeutics.
6 people are employed at Renova Therapeutics.
Renova Therapeutics is based in San Diego, California.
The NAICS codes for Renova Therapeutics are [32, 325, 3254, 32541].
The SIC codes for Renova Therapeutics are [28, 283].